The most recent 13F filing that Royce & Associates LP submitted to the Securities and Exchange Commission revealed that the company’s holdings in Innospec Inc. (NASDAQ: IOSP) were reduced by 1.9% during the third quarter. Royce & Associates LP is an investment management firm. The institutional investor has a total of 1,047,688 shares of the company’s stock in their possession following the sale of 20,636 shares of the specialty chemicals company’s stock during the time frame in question. Royce & Associates LP’s third-largest holding is Innospec, which represents 1% of the total value of the company’s investment portfolio. Royce & Associates LP is a limited partnership. The most recent filing that Royce & Associates LP has made with the SEC indicates that the company has an ownership interest in approximately 4.23% of Innospec, which is currently valued at $89,755,000.
There have been transactions involving shares of IOPS carried out by other hedge funds in addition to those already mentioned. PNC Financial Services Group Inc. increased the Innospec stock held by 8.6% over the year’s first three months. PNC Financial Services Group Inc. is now the owner of the specialty chemicals company’s stock, which has a value of $165,000; this was accomplished through the acquisition of an additional 141 shares during the most recent quarter. PNC Financial Services Group, Inc., abbreviated as PNC During the second quarter, Nisa Investment Advisors LLC completed a 10.6% increase in the amount of Innospec stock held in its portfolio. During the most recent quarter, Nisa Investment Advisors LLC increased its holdings in the stock of the specialty chemicals business by 180 shares, bringing its total number of shares to 1,872, which have a value of $179,000. The Maryland State Retirement and Pension System increased the amount of Innospec stock owned by 2.0% over the second quarter. The Maryland State Retirement and Pension System is now the owner of 10,080 shares held by the specialty chemicals company. This brings about the result of the most recent quarter’s additional purchase of 197 shares of the company’s stock. There is a current value of $966,00 attached to these shares. DURING THE SECOND QUARTER, Price T. Rowe Associates Inc. (MD) brought the total number of shares it owned in Innospec to a level that was 1.0% higher than before. Price T. Rowe Associates Inc. (MD) now has 20,364 shares in the specialty chemicals business after purchasing an additional 200 shares during the most recent quarter. This brings the company’s total number of shares to 20,364. The value of these shares as of right now is $1,951,000 in total. Finally, but certainly not least, during the first three months of 2018, Captrust Financial Advisors increased the amount of Innospec stock owned by 74.7%. The specialty chemicals company’s stock was increased to a total of 498 shares for Captrust Financial Advisors’ portfolio following the acquisition of an additional 213 shares during the most recent fiscal quarter. There is a value of $46,000 associated with these shares. Institutional investors and hedge funds are the current owners of 94.97% of the company’s stock.
In a separate research report made accessible to the general public on Monday, December 19, StockNews.com changed its recommendation for Innospec from “strong buy” to “buy.”
When trading started on Thursday, the price of a share of Innospec was $111.28 per share. The company’s market capitalization is estimated to be $2.76 billion, while its price-to-earnings ratio stands at 21.16 and its beta stands at 1.16. The company’s simple moving average over the past 50 days is $107.44, and its simple moving average over the past 200 days is $98.81. During the previous twelve months, the share price of Innospec Inc. ranged from as low as $83.13 to as high as $115.65.
Innospec (NASDAQ: IOSP) made the findings of its most recent quarterly earnings report available to the public on Tuesday, November 8. The company specializing in specialty chemicals reported earnings of $1.74 per share for its most recent quarter, which is $0.34 higher than the consensus estimate of $1.40 per share. The revenue for the quarter came in at $513,000,000, which is significantly higher than the consensus estimate of $468.35,000,000 given for that figure. The return on equity for Innospec was calculated to be 14.37%, and the net margin for the company was calculated to be 7.04%. According to forecasts from analysts who follow the pharmaceutical and biotechnology industries, Innospec Inc. will likely achieve a profit of 6.22 cents per share during the current financial year.
In addition, the business decided to begin disbursing a dividend once every six months, and the first dividend was handed out on November 28 of this year. On Monday, November 21, shareholders of record were each given a dividend payment of $0.65. This payment was made. This past Friday, November 18, was the deadline for customers to submit their payment to receive the dividend. This represents an increase from the previous dividend payment that Innospec made, which was $0.63 semi-annually. As a consequence of this, the yield that we obtain is 1.2%. Currently, 24.71 percent of Innospec’s profits are distributed to shareholders.
In other news, on Monday, December 5, David B. Jones, the company’s senior vice president, purchased 752 shares of company stock. This was disclosed in a press release. The stock purchase came to a total cost of 81,208.48 dollars, which works out to a price of $107.99 per share on average. As a direct result of the acquisition, the senior vice president now owns 1,530 business shares with a combined value of approximately $165,224.70. These shares have been given to the senior vice president. The transaction was announced in a document that was released by the SEC, and that document can be found on the website of the SEC. The current percentage of company stock owned by company insiders is 1.52%.